Antiviral research
SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19.
Charlotte Hedskog, Lauren Rodriguez, Yu Hu, Jiani Li, Dong Han, Nadine Peinovich, Clarissa Martinez, Pui Yan Ho, Jason K Perry, Juan Maria González Del Castillo, Yiannis Koullias, Ross Martin, Robert H Hyland
Published: 202610.1016/j.antiviral.2026.106351
Abstract
Obeldesivir is an oral nucleoside analog prodrug that targets and inhibits the SARS-CoV-2 RNA-dependent RNA polymerase Nsp12. This study evaluated the development of obeldesivir resistance in participants from the Phase 3, multicenter, double-blind B…
Preview only. Read the full abstract at the source